Comparing two plasma concentration profiles [Study As­sess­ment]

posted by Darborn – Taiwan, 2025-10-21 03:02 (245 d 04:30 ago) – Posting: # 24468
Views: 3,417

Hi Helmut,

I may add some background information.
China's regulatory agency (NMPA/CDE) refused to approve multiple highly-variable products which conducted their bioequivalence study in a four-period crossover design. The reason for this acion was based on "The similarity of plasma-concentration curves of the same subject between TEST and REFERENCE is larger than the similarity between two repeated REFERENCE".
I tried to calculate the f2 factor using the Cmax value of the reference product as a correction factor, and I found many different products had a similar pattern that "The similarity of plasma-concentration curves of the same subject between TEST and REFERENCE is larger than the similarity between two repeated REFERENCE".
I believe this is due to the nature of highly-variable products and randomness, but I am not sure if this is correct. Does FDA or EMA have similar statments?

Thanks

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
108 visitors (0 registered, 108 guests [including 16 identified bots]).
Forum time: 07:32 CEST (Europe/Vienna)

Competence, like truth, beauty and contact lenses,
is in the eye of the beholder.    Laurence J. Peter

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5